Sign In
Last checked at 
10 Oct 2014 11:44
ο»Ώ
Β
Β
Β
Β
PRESS RELEASE
Β
Β
Hikma update on colchicine
Β
London, 10 October 2014 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today notes that the United States District Court for the District of Delaware has granted Takeda Pharmaceuticals U.S.A., Inc.'s ("Takeda") motion for a temporary restraining order in relation to further distribution of Hikma's FDA-approved colchicine 0.6mg capsules for the prophylaxis of gout flares, while the court considers Takeda's motion for a preliminary injunction.
Β
Hikma received FDA approval of its New Drug Application for colchicine 0.6mg capsules on 30 September 2014.
Β
The litigation will continue later this month and Hikma will work constructively for a positive outcome.
Β
Β
-- ENDS --
Β
Β
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal, VP Corporate Strategy and Director of Investor Relations +44 (0)20 7399 2760
Lucinda Henderson, Deputy Investor Relations Director +44 (0)20 7399 2765
Β
FTI Consulting
Ben Atwell/ Matthew Cole/ Julia Phillips +44 (0)20 3727 1000
Β
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: "Branded", "Injectables" and "Generics", based principally in the Middle East and North Africa ("MENA"), where it is a market leader, the United States and Europe. In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million.
Β
Β
Follow the stocks
